WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018102314) POLYMORPHIC FORM OF SEPIAPTERIN
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/102314    International Application No.:    PCT/US2017/063515
Publication Date: 07.06.2018 International Filing Date: 28.11.2017
IPC:
C07D 475/04 (2006.01), C07D 475/00 (2006.01)
Applicants: CENSA PHARMACEUTICALS INC. [US/US]; 65 William Street Suite #200t Wellesley, MA 02481 (US).
YOSHINO, Hiroshi [JP/JP]; (JP).
KOMODA, Taichi [JP/JP]; (JP).
SHIRATORI PHARMACEUTICALS CO., LTD. [JP/JP]; 2-3-7 Akenehama Narashino-shi (JP).
MATSUMOTO, Takayoshi [JP/JP]; (JP).
KISHIMOTO, Kaito [JP/JP]; (JP).
MURATA, Shunichi [JP/JP]; (JP).
SHIRO, Yuichi [JP/JP]; (JP)
Inventors: YOSHINO, Hiroshi; (JP).
KOMODA, Taichi; (JP).
MATSUMOTO, Takayoshi; (JP).
KISHIMOTO, Kaito; (JP).
MURATA, Shunichi; (JP).
SHIRO, Yuichi; (JP).
LEVY, Daniel, E.; (US)
Agent: BIEKER-BRADY, Kristina; (US)
Priority Data:
62/427,686 29.11.2016 US
Title (EN) POLYMORPHIC FORM OF SEPIAPTERIN
(FR) FORME POLYMORPHE DE SÉPIAPTÉRINE
Abstract: front page image
(EN)Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular BH4 levels or with dysfunction of various BH4 dependent metabolic pathways, which involves administering to the patient an effective amount of the crystalline form.
(FR)L'invention concerne une forme cristalline de sépiaptérine, un procédé de préparation de la forme cristalline, des compositions pharmaceutiques contenant la forme cristalline, et un procédé de traitement de patients atteints d'une maladie associée à de faibles niveaux de BH4 intracellulaire ou avec un dysfonctionnement de diverses voies métaboliques dépendant de BH4, qui consiste à administrer au patient une quantité efficace de la forme cristalline.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)